Sprycel (dasatinib), a new oral drug in Canada for chronic myeloid leukemia (CML)
May 2007
There's a lot of excitement about Sprycel (dasatinib), a new oral drug in Canada for chronic myeloid leukemia (CML).
It's for patients who are resistant to or can't take other treatments...including Gleevec (imatinib).
It's a tyrosine kinase inhibitor...similar to Gleevec.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive